D DBV Technologies SA
D
Chiusa
2.32 0.09
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
2.278
Massimo
2.366
Entrata | -2.8M -50M |
|---|---|
Vendite | -200K 700K |
EPS | -0.05 |
Margine di Profitto | -7,200 |
Dipendenti | 170 |
EBITDA | -1.2M -47M |
Utili prossimi | 28 ott 2026 |
|---|
Capitalizzazione di Mercato | -146M 687M |
|---|---|
Apertura precedente | 2.23 |
Chiusura precedente | 2.32 |
DBV Technologies SA Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
DBV Technologies SA Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.